JP2022532918A5 - - Google Patents
Info
- Publication number
- JP2022532918A5 JP2022532918A5 JP2021568893A JP2021568893A JP2022532918A5 JP 2022532918 A5 JP2022532918 A5 JP 2022532918A5 JP 2021568893 A JP2021568893 A JP 2021568893A JP 2021568893 A JP2021568893 A JP 2021568893A JP 2022532918 A5 JP2022532918 A5 JP 2022532918A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- branched
- linear
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025150534A JP2025183333A (ja) | 2019-05-20 | 2025-09-10 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850098P | 2019-05-20 | 2019-05-20 | |
| US62/850,098 | 2019-05-20 | ||
| PCT/US2020/033615 WO2020236825A2 (en) | 2019-05-20 | 2020-05-19 | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025150534A Division JP2025183333A (ja) | 2019-05-20 | 2025-09-10 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532918A JP2022532918A (ja) | 2022-07-20 |
| JP2022532918A5 true JP2022532918A5 (enExample) | 2023-07-13 |
| JP7743312B2 JP7743312B2 (ja) | 2025-09-24 |
Family
ID=70978687
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568870A Active JP7663514B2 (ja) | 2019-05-20 | 2020-05-19 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| JP2021568893A Active JP7743312B2 (ja) | 2019-05-20 | 2020-05-19 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| JP2025150534A Pending JP2025183333A (ja) | 2019-05-20 | 2025-09-10 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568870A Active JP7663514B2 (ja) | 2019-05-20 | 2020-05-19 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025150534A Pending JP2025183333A (ja) | 2019-05-20 | 2025-09-10 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20230092679A1 (enExample) |
| EP (2) | EP3972651A2 (enExample) |
| JP (3) | JP7663514B2 (enExample) |
| KR (2) | KR20220024106A (enExample) |
| CN (2) | CN114728076A (enExample) |
| AR (1) | AR122270A1 (enExample) |
| AU (2) | AU2020279979A1 (enExample) |
| BR (1) | BR112021023229A2 (enExample) |
| CA (2) | CA3138058A1 (enExample) |
| CL (1) | CL2021003042A1 (enExample) |
| CO (1) | CO2021016552A2 (enExample) |
| DO (1) | DOP2021000238A (enExample) |
| GE (2) | GEP20257822B (enExample) |
| IL (2) | IL288110A (enExample) |
| JO (1) | JOP20210289A1 (enExample) |
| MX (1) | MX2021014094A (enExample) |
| PE (1) | PE20220218A1 (enExample) |
| PH (1) | PH12021552831A1 (enExample) |
| PY (1) | PY2020118A (enExample) |
| SG (1) | SG11202112056PA (enExample) |
| TW (1) | TW202100184A (enExample) |
| UY (1) | UY38700A (enExample) |
| WO (2) | WO2020236825A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326516A (en) * | 2020-01-07 | 2026-04-01 | Purdue Research Foundation | Targeted steroid compounds |
| HRP20240979T1 (hr) * | 2020-05-19 | 2024-10-25 | Les Laboratoires Servier | Para-amino-benzil povezivači, postupak njihove pripreme i njihova upotreba u konjugatima |
| ES2963150T3 (es) | 2020-10-27 | 2024-03-25 | Elucida Oncology Inc | Procedimientos para funcionalizar nanopartículas |
| CN116761635A (zh) | 2020-11-24 | 2023-09-15 | 诺华股份有限公司 | Bcl-xl抑制剂抗体药物缀合物及其使用方法 |
| JP2023553808A (ja) * | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| TWI861509B (zh) * | 2021-06-11 | 2024-11-11 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
| JP7900421B2 (ja) | 2021-06-11 | 2026-08-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ |
| US20240299558A1 (en) * | 2021-06-18 | 2024-09-12 | University Of Maryland, Baltimore | Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof |
| US20230212181A1 (en) * | 2022-01-01 | 2023-07-06 | Aarvik Therapeutics, Inc. | Double payload cancer therapeutics |
| IL317101A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of anticancer compounds and methods of using them |
| KR20250011947A (ko) | 2022-05-20 | 2025-01-22 | 노파르티스 아게 | 항체 약물 콘쥬게이트 |
| JPWO2023234427A1 (enExample) * | 2022-06-03 | 2023-12-07 | ||
| AU2023279443A1 (en) * | 2022-06-03 | 2025-01-23 | Ube Corporation | Antibody-multidrug conjugate |
| EP4536278A4 (en) | 2022-06-07 | 2026-08-12 | Actinium Pharmaceuticals Inc | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| EP4572802A1 (en) * | 2022-08-17 | 2025-06-25 | Lonza Sales AG | Extracellular vesicle comprising a biologically active molecule and a dual cleavable linker |
| EP4572801A1 (en) * | 2022-08-17 | 2025-06-25 | Lonza Sales AG | Extracellular vesicle comprising a biologically active molecule and a cleavable linker |
| US20260166169A1 (en) * | 2022-10-19 | 2026-06-18 | Multitude Therapeutics Inc. | Antibody-drug conjugate, preparation method and use thereof |
| KR20260007619A (ko) * | 2023-05-09 | 2026-01-14 | 상하이 헨리우스 바이오테크, 인크. | 항-pdl1 항체-약물 접합체 및 응용 |
| CN121263211A (zh) * | 2023-05-09 | 2026-01-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗表皮生长因子受体(egfr)抗体-药物偶联物及其应用 |
| CN117229190A (zh) * | 2023-06-06 | 2023-12-15 | 武汉翱飞科技有限公司 | 一种马来酰亚胺型连接子及其制备方法与应用 |
| WO2025106634A1 (en) * | 2023-11-17 | 2025-05-22 | Genentech, Inc. | Mcl-1 inhibitor compounds and use in antibody drug conjugates |
| UY40985A (es) | 2023-11-22 | 2025-06-30 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| EP1472275B1 (en) | 2002-02-05 | 2008-12-17 | Genentech, Inc. | Protein purification |
| KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-ｃｄ74 항체 및 그 이용방법 |
| DK1578446T3 (en) | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| PE20110217A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| BRPI1015234A2 (en) | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| EP2714737A1 (en) | 2011-05-27 | 2014-04-09 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| SG11201407017WA (en) | 2012-06-04 | 2014-12-30 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
| US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
| AU2013350802B2 (en) | 2012-11-30 | 2016-07-14 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
| WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| EA201591465A1 (ru) | 2013-02-08 | 2015-12-30 | АйАрЭм ЭлЭлСи | Специфичные участки для модификации антител для получения иммуноконъюгатов |
| NZ710385A (en) | 2013-02-19 | 2016-10-28 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| US9498532B2 (en) * | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| MX366978B (es) * | 2013-03-15 | 2019-08-01 | Novartis Ag | Conjugados de anticuerpo - farmaco. |
| FR3008975A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| UA118113C2 (uk) * | 2013-12-16 | 2018-11-26 | Дженентек, Інк. | Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом |
| FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| BR112016020065A2 (pt) | 2014-03-12 | 2018-02-20 | Novartis Ag | sítios específicos para modificar anticorpos para fazer imunoconjugados |
| MA39740A (fr) | 2014-03-13 | 2017-01-18 | Hoffmann La Roche | Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| UY36401A (es) * | 2014-11-14 | 2016-06-30 | Novartis Ag | Conjugados anticuerpos-fármacos |
| RU2017123942A (ru) | 2014-12-09 | 2019-01-11 | Эббви Инк. | Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их |
| JP2018502839A (ja) | 2014-12-09 | 2018-02-01 | アッヴィ・インコーポレイテッド | Ｂｃｌ−ｘＬ阻害性化合物およびこれを含む抗体薬物コンジュゲート |
| EP3229844B1 (en) | 2014-12-09 | 2020-03-04 | AbbVie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037958B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP3165536A1 (en) * | 2015-11-09 | 2017-05-10 | Ludwig-Maximilians-Universität München | Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition |
| FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| CR20180499A (es) | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
| MX2018015272A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
| CN109641962A (zh) | 2016-06-08 | 2019-04-16 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| MX2018015284A (es) | 2016-06-08 | 2019-09-18 | Abbvie Inc | Conjugados de anticuerpo anti-egfr y fármaco. |
| CN109562190A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
| MX2018015268A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
| CN116059201A (zh) | 2016-06-08 | 2023-05-05 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
| RS61828B1 (sr) | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
| JP2019526529A (ja) | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート |
| AU2017355402A1 (en) * | 2016-11-02 | 2019-05-30 | Health Research, Inc. | Combination treatment with antibody-drug conjugates and PARP inhibitors |
| US11434301B2 (en) | 2016-11-11 | 2022-09-06 | The Regents Of The University Of California | Anti-CD46 antibodies and methods of use |
| WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| EP3617221A4 (en) * | 2017-04-19 | 2021-04-14 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | CYTOTOXIN AND CONJUGATE, USES THEREOF AND MANUFACTURING PROCESSES THEREFORE |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| UA126813C2 (uk) * | 2017-08-01 | 2023-02-08 | Медімм'Юн, Ллк | Моноклональний кон’югат антитіло-лікарський засіб до bcma |
| AU2018317828A1 (en) | 2017-08-15 | 2020-04-02 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| MX2020001719A (es) | 2017-08-15 | 2020-11-06 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y metodos de uso. |
| CR20200124A (es) | 2017-08-15 | 2020-09-28 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y métodos de uso |
| TW201922294A (zh) * | 2017-10-31 | 2019-06-16 | 美商伊繆諾金公司 | 抗體-藥物結合物與阿糖胞苷之組合治療 |
| JP7458997B2 (ja) * | 2018-05-29 | 2024-04-01 | ブリストル－マイヤーズ スクイブ カンパニー | プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法 |
| EP3807644A4 (en) * | 2018-06-12 | 2022-07-06 | Angiex, Inc. | ANTIBODY-OLIGONUCLEOTIDE CONJUGATES |
-
2020
- 2020-05-19 AU AU2020279979A patent/AU2020279979A1/en active Pending
- 2020-05-19 US US17/613,006 patent/US20230092679A1/en active Pending
- 2020-05-19 JP JP2021568870A patent/JP7663514B2/ja active Active
- 2020-05-19 WO PCT/US2020/033615 patent/WO2020236825A2/en not_active Ceased
- 2020-05-19 PY PY202002020118A patent/PY2020118A/es unknown
- 2020-05-19 JP JP2021568893A patent/JP7743312B2/ja active Active
- 2020-05-19 PE PE2021001880A patent/PE20220218A1/es unknown
- 2020-05-19 WO PCT/US2020/033602 patent/WO2020236817A2/en not_active Ceased
- 2020-05-19 EP EP20733328.7A patent/EP3972651A2/en active Pending
- 2020-05-19 GE GEAP202015825A patent/GEP20257822B/en unknown
- 2020-05-19 BR BR112021023229A patent/BR112021023229A2/pt unknown
- 2020-05-19 PH PH1/2021/552831A patent/PH12021552831A1/en unknown
- 2020-05-19 KR KR1020217041613A patent/KR20220024106A/ko not_active Withdrawn
- 2020-05-19 UY UY0001038700A patent/UY38700A/es active IP Right Grant
- 2020-05-19 CN CN202080043826.XA patent/CN114728076A/zh active Pending
- 2020-05-19 CA CA3138058A patent/CA3138058A1/en active Pending
- 2020-05-19 TW TW109116585A patent/TW202100184A/zh unknown
- 2020-05-19 MX MX2021014094A patent/MX2021014094A/es unknown
- 2020-05-19 AR ARP200101417A patent/AR122270A1/es unknown
- 2020-05-19 US US17/613,020 patent/US20230081720A1/en active Pending
- 2020-05-19 EP EP20730922.0A patent/EP3972649B1/en active Active
- 2020-05-19 KR KR1020217041091A patent/KR20220017931A/ko active Pending
- 2020-05-19 SG SG11202112056PA patent/SG11202112056PA/en unknown
- 2020-05-19 CN CN202080052440.5A patent/CN114728077A/zh active Pending
- 2020-05-19 GE GEAP202515825A patent/GEAP202515825A/en unknown
- 2020-05-19 CA CA3136088A patent/CA3136088A1/en active Pending
- 2020-05-19 AU AU2020279230A patent/AU2020279230A1/en active Pending
-
2021
- 2021-10-27 JO JOP/2021/0289A patent/JOP20210289A1/ar unknown
- 2021-11-14 IL IL288110A patent/IL288110A/en unknown
- 2021-11-15 IL IL288117A patent/IL288117A/en unknown
- 2021-11-17 CL CL2021003042A patent/CL2021003042A1/es unknown
- 2021-11-18 DO DO2021000238A patent/DOP2021000238A/es unknown
- 2021-12-06 CO CONC2021/0016552A patent/CO2021016552A2/es unknown
-
2025
- 2025-09-10 JP JP2025150534A patent/JP2025183333A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533400A5 (enExample) | ||
| WO2023078021A1 (en) | Bcma monoclonal antibody and the antibody-drug conjugate | |
| AU2021290341B2 (en) | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups | |
| KR102914483B1 (ko) | 가교-결합된 피롤로벤조다이아제핀 이량체(pbd) 유도체 및 이의 접합체 | |
| KR102434308B1 (ko) | 아르기닌 활성 억제용 조성물 및 방법 | |
| EP3130608B1 (en) | (anti-her2 antibody)-drug conjugate | |
| CN109912683B (zh) | 一种细胞毒素分子、偶联物及其制备方法和应用 | |
| CA3016172C (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
| JP2023553808A5 (enExample) | ||
| CA2921982C (en) | Novel cytotoxic agents for conjugation of drugs to cell binding molecule | |
| RU2664465C2 (ru) | Конъюгат антитело-лекарственное средство | |
| EP3604311A1 (en) | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof | |
| CA3136088A1 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| WO2022199237A1 (zh) | 修饰的氨基酸及其在adc中的应用 | |
| WO2024239281A1 (en) | Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate | |
| TWI785334B (zh) | 一種細胞結合分子-tubulysin衍生物偶聯物及其製備方法 | |
| JP2023553811A5 (enExample) | ||
| CA2990300A1 (en) | Site specific homogeneous conjugates with ksp inhibitors | |
| CA3202759A1 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| CN105641707A (zh) | 细胞毒素分子同细胞结合受体分子的共轭体 | |
| CA3129581A1 (en) | Antibody-drug conjugates including antibody against human dlk1, and use thereof | |
| WO2025233682A1 (en) | Antibody drug conjugates comprising sting agonists and uses thereof | |
| RU2021137408A (ru) | Конъюгаты антитело-лекарственное средство ингибитора MCL-1 и способы их применения | |
| RU2021137422A (ru) | Конъюгаты антитело-лекарственное средство ингибитора mcl-1 и способы их применения | |
| RU2801630C2 (ru) | Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение |